Price
CHART BY
Frequently asked questions
What is Uniqure's market capitalization?
The market capitalization of Uniqure is $3.39B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Uniqure?
Uniqure's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$3.921. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Uniqure's stock?
Currently, 14 analysts cover Uniqure's stock, with a consensus target price of $65.67. Analyst ratings provide insights into the stock's expected performance.
What is Uniqure's revenue over the trailing twelve months?
Over the trailing twelve months, Uniqure reported a revenue of $14.34M.
What is the EBITDA for Uniqure?
Uniqure's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$164.49M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Uniqure?
Uniqure has a free cash flow of -$175.30M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Uniqure have, and what sector and industry does it belong to?
Uniqure employs approximately 209 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of Uniqure's shares?
The free float of Uniqure is 54.63M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $3.39B
- EPS (TTM)
- -$3.921
- Free Float
- 54.63M
- Revenue (TTM)
- $14.34M
- EBITDA (TTM)
- -$164.49M
- Free Cashflow (TTM)
- -$175.30M
Pricing
- 1D span
- $54.42$54.81
- 52W span
- $4.83$60.65
Analyst Ratings
The price target is $65.67 and the stock is covered by 14 analysts.
Buy
13
Hold
1
Sell
0
Information
uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.
- Employees
- 209
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- ISIN
- NL0010696654
- Primary Ticker
- QURE
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet